Jitesh Chauhan
Overview
Explore the profile of Jitesh Chauhan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
246
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grandits M, Palhares L, Osborn G, Chauhan J, Stoker K, Sow H, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40074330
Background: Anti-human epidermal growth factor receptor 2 (HER2) IgG1-based antibody therapies significantly improve cancer prognosis, yet intrinsic or acquired resistance to fragment antigen-binding (Fab)-mediated direct effects commonly occurs. Most resistant...
2.
Stavraka C, Chauhan J, Crescioli S, McSweeney S, Pope A, Gillett C, et al.
Allergy
. 2025 Mar;
PMID: 40045925
Background: IgE antibodies directed against cancer antigens have demonstrated potent anti-tumour effects in pre-clinical studies. MOv18 IgE, the first-in-class IgE recognising the cancer antigen folate receptor alpha (FRα), showed preliminary...
3.
Silva G, Chauhan J, Leung A, Eigenmann P
Pediatr Allergy Immunol
. 2025 Feb;
36(2):e70050.
PMID: 39995277
No abstract available.
4.
Palhares L, Grandits M, Stoker K, Chauhan J, Sow H, Fruhwirth G, et al.
J Exp Clin Cancer Res
. 2025 Feb;
44(1):49.
PMID: 39934835
Background: Tumor-targeting IgE antibodies have elicited potent tumor-restricting effects by recruiting immune effector mechanisms. However, a dedicated platform for the generation, selection and evaluation of novel IgEs based on target...
5.
Bax H, Chauhan J, McCraw A, Grandits M, Stavraka C, Lentfer H, et al.
MAbs
. 2025 Jan;
17(1):2451295.
PMID: 39833133
Antibodies used for cancer therapy are monoclonal IgGs, but tumor-targeting IgE antibodies have shown enhanced effector cell potency against cancer in preclinical models. Research-grade recombinant IgE antibodies have been generated...
6.
Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma
Chen X, Habib S, Alexandru M, Chauhan J, Evan T, Troka J, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39409881
Immunotherapies, including checkpoint inhibitor antibodies, have precipitated significant improvements in clinical outcomes for melanoma. However, approximately half of patients do not benefit from approved treatments. Additionally, apart from Tebentafusp, which...
7.
Cavaleiro Rufo J, Chauhan J, Kalayci O, Eigenmann P
Pediatr Allergy Immunol
. 2024 Sep;
35(9):e14242.
PMID: 39286994
No abstract available.
8.
Pascal M, Bax H, Bergmann C, Bianchini R, Castells M, Chauhan J, et al.
Allergy
. 2024 Jul;
79(9):2319-2345.
PMID: 39036854
Derived from the myeloid lineage, granulocytes, including basophils, eosinophils, and neutrophils, along with mast cells, play important, often disparate, roles across the allergic disease spectrum. While these cells and their...
9.
Santaolalla A, Bax H, Chauhan J, Josephs D, Van Hemelrijck M, Karagiannis S
Clin Exp Allergy
. 2024 Jan;
54(4):297-299.
PMID: 38226782
No abstract available.
10.
Spicer J, Basu B, Montes A, Banerji U, Kristeleit R, Miller R, et al.
Nat Commun
. 2023 Jul;
14(1):4180.
PMID: 37491373
All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report...